~~<i id='A63675B46C'><strike id='A63675B46C'><tt id='A63675B46C'><pre id='A63675B46C'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

entertainment

author：leisure time 2025-08-23 03:44:59 - browse：25767

The Food and Drug Administration said on Friday that it has some safety concerns about an experimental CRISPR-based treatment for sickle cell disease, citing the methods used by its makers to evaluate the risk of inadvertently making unwanted changes to patients’ DNA.

None of the concerns raised by the FDA on Friday, however, suggest the agency is reluctant to approve the treatment, called exa-cel, which is being developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

Exa-cel, given as a one-time infusion, uses CRISPR genome-editing technology to patch up the genetic faults at the root of sickle cell disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： The creative science of coining drug names

focus

Wikipedia

hotspot

Wikipedia

hotspot

AdobeUsuallythewordsgenerativeAIinhealtharefollowedbyaboldclaim.Thetechnologywilltransformsomeaspect

WSS

AI for drug discovery: Experts on separating hype from reality

AltruBio raises $225 million to develop ulcerative colitis drug

Flagship Pioneering startup Sonata Therapeutics lays off 21

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Black vets could get higher VA benefits if race not used in lung test

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

hotspot

entertainment

focus

Novavax promises a turnaround & Lilly roils the obesity market

Hospitals are piloting generative AI tools as regulators play catch

After affirmative action ruling, medical educators look to 'holistic review'

In 'major milestone,' FDA approves first cell therapy for solid tumors

Drug repurposing or repositioning? The language matters

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

The cancer drug shortage isn’t new — and neither are the solutions

Brain technologies pose threats that are all too real, experts warn

Affirmative action in medical school literally saved lives

Can gargling with Listerine treat gonorrhea of the mouth?

focus

Is it ever OK for doctors to lie to their patients?

Surprise medical billing ban raises prices elsewhere

Empower primary care with adequate payments and technology

Measles policy set amid Florida outbreak alarms vaccine proponents

As AI regulations shape up, health tech startups beg for clarity

Primary care doctor shortage won't be solved by free med school tuition

Wikipedia

hotspot

Wikipedia

hotspot